论文部分内容阅读
支气管哮喘(哮喘)是儿童期最常见的慢性疾病,吸入糖皮质激素(ICS)仍是目前哮喘治疗中最有效的方法。但由于本身存在的不良反应,使其在临床应用中受到一定的影响。通过对近年国内外相关文献进行综述,认为短期吸入中小剂量糖皮质激素(GC)对哮喘儿童的身高无显著性影响。对长期吸入者身高的影响与ICS的种类、剂量、疗程、吸入器、吸入技术、不同年龄以及个体对激素的敏感程度等有关,可采取一定的措施预防ICS对身高的影响。
Bronchial asthma (asthma) is the most common chronic disease in childhood, and inhaled glucocorticoid (ICS) remains the most effective current treatment for asthma. However, due to its own adverse reactions to make it in clinical applications have been affected. Through reviewing the relevant literatures at home and abroad in recent years, it is concluded that short-term inhaled small and medium dose glucocorticoid (GC) has no significant effect on the height of asthmatic children. The effect on the long-term inhabitant height is related to the type of ICS, dose, duration of treatment, inhaler, inhalation technique, age, and the individual’s sensitivity to hormones. Certain measures may be taken to prevent the effects of ICS on height.